380 related articles for article (PubMed ID: 33145616)
1. Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types.
Terranova N; Jansen M; Falk M; Hendriks BS
Cancer Chemother Pharmacol; 2021 Feb; 87(2):185-196. PubMed ID: 33145616
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours.
Middleton MR; Dean E; Evans TRJ; Shapiro GI; Pollard J; Hendriks BS; Falk M; Diaz-Padilla I; Plummer R
Br J Cancer; 2021 Aug; 125(4):510-519. PubMed ID: 34040175
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours.
Shapiro GI; Wesolowski R; Devoe C; Lord S; Pollard J; Hendriks BS; Falk M; Diaz-Padilla I; Plummer R; Yap TA
Br J Cancer; 2021 Aug; 125(4):520-527. PubMed ID: 34040174
[TBL] [Abstract][Full Text] [Related]
4. Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
Yap TA; O'Carrigan B; Penney MS; Lim JS; Brown JS; de Miguel Luken MJ; Tunariu N; Perez-Lopez R; Rodrigues DN; Riisnaes R; Figueiredo I; Carreira S; Hare B; McDermott K; Khalique S; Williamson CT; Natrajan R; Pettitt SJ; Lord CJ; Banerji U; Pollard J; Lopez J; de Bono JS
J Clin Oncol; 2020 Sep; 38(27):3195-3204. PubMed ID: 32568634
[TBL] [Abstract][Full Text] [Related]
5. Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma.
Talele S; Zhang W; Burgenske DM; Kim M; Mohammad AS; Dragojevic S; Gupta SK; Bindra RS; Sarkaria JN; Elmquist WF
J Pharmacol Exp Ther; 2021 Dec; 379(3):343-357. PubMed ID: 34556535
[TBL] [Abstract][Full Text] [Related]
6. A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer.
Plummer R; Dean E; Arkenau HT; Redfern C; Spira AI; Melear JM; Chung KY; Ferrer-Playan J; Goddemeier T; Locatelli G; Dong J; Fleuranceau-Morel P; Diaz-Padilla I; Shapiro GI
Lung Cancer; 2022 Jan; 163():19-26. PubMed ID: 34894455
[TBL] [Abstract][Full Text] [Related]
7. Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy.
Gorecki L; Andrs M; Rezacova M; Korabecny J
Pharmacol Ther; 2020 Jun; 210():107518. PubMed ID: 32109490
[TBL] [Abstract][Full Text] [Related]
8. CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method.
Javed SR; Lord S; El Badri S; Harman R; Holmes J; Kamzi F; Maughan T; McIntosh D; Mukherjee S; Ooms A; Radhakrishna G; Shaw P; Hawkins MA
Br J Cancer; 2024 Feb; 130(3):467-475. PubMed ID: 38129525
[TBL] [Abstract][Full Text] [Related]
9. Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor.
Knegtel R; Charrier JD; Durrant S; Davis C; O'Donnell M; Storck P; MacCormick S; Kay D; Pinder J; Virani A; Twin H; Griffiths M; Reaper P; Littlewood P; Young S; Golec J; Pollard J
J Med Chem; 2019 Jun; 62(11):5547-5561. PubMed ID: 31074988
[TBL] [Abstract][Full Text] [Related]
10. A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer.
Konstantinopoulos PA; da Costa AABA; Gulhan D; Lee EK; Cheng SC; Hendrickson AEW; Kochupurakkal B; Kolin DL; Kohn EC; Liu JF; Stover EH; Curtis J; Tayob N; Polak M; Chowdhury D; Matulonis UA; Färkkilä A; D'Andrea AD; Shapiro GI
Nat Commun; 2021 Sep; 12(1):5574. PubMed ID: 34552099
[TBL] [Abstract][Full Text] [Related]
11. The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines.
Schnoell J; Sparr C; Al-Gboore S; Haas M; Brkic FF; Kadletz-Wanke L; Heiduschka G; Jank BJ
Invest New Drugs; 2023 Dec; 41(6):842-850. PubMed ID: 37934325
[TBL] [Abstract][Full Text] [Related]
12. Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents.
Jo U; Senatorov IS; Zimmermann A; Saha LK; Murai Y; Kim SH; Rajapakse VN; Elloumi F; Takahashi N; Schultz CW; Thomas A; Zenke FT; Pommier Y
Mol Cancer Ther; 2021 Aug; 20(8):1431-1441. PubMed ID: 34045232
[TBL] [Abstract][Full Text] [Related]
13. Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.
Kurmasheva RT; Kurmashev D; Reynolds CP; Kang M; Wu J; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28921800
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies.
Edlund H; Lee SK; Andrew MA; Slatter JG; Aksenov S; Al-Huniti N
Clin Pharmacokinet; 2019 May; 58(5):659-672. PubMed ID: 30556110
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 Studies.
Dosne AG; Valade E; Stuyckens K; Li LY; Ouellet D; Perez-Ruixo JJ
J Clin Pharmacol; 2020 Apr; 60(4):515-527. PubMed ID: 31742712
[TBL] [Abstract][Full Text] [Related]
17. Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.
Telli ML; Tolaney SM; Shapiro GI; Middleton M; Lord SR; Arkenau HT; Tutt A; Abramson V; Dean E; Haddad TC; Wesolowski R; Ferrer-Playan J; Goddemeier T; Grombacher T; Dong J; Fleuranceau-Morel P; Diaz-Padilla I; Plummer R
NPJ Breast Cancer; 2022 Apr; 8(1):45. PubMed ID: 35393425
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancers.
Zhou H; Choi L; Lau H; Bruntsch U; Vries EE; Eckhardt G; Oosterom AT; Verweij J; Schran H; Barbet N; Linnartz R; Capdeville R
J Clin Pharmacol; 2000 Mar; 40(3):275-83. PubMed ID: 10709156
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors.
Jackson CB; Noorbakhsh SI; Sundaram RK; Kalathil AN; Ganesa S; Jia L; Breslin H; Burgenske DM; Gilad O; Sarkaria JN; Bindra RS
Cancer Res; 2019 Sep; 79(17):4331-4338. PubMed ID: 31273061
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
Han K; Jin JY; Marchand M; Eppler S; Choong N; Hack SP; Tikoo N; Bruno R; Dresser M; Musib L; Budha NR
Cancer Chemother Pharmacol; 2015 Nov; 76(5):917-24. PubMed ID: 26365290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]